CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 …
See more here:
Cornerstone Pharmaceuticals' CPI-613 Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting …